On December 7, 2025, Sarepta Therapeutics, Inc. granted CEO Douglas Ingram equity awards valued at approximately $12 million, split between time-based RSUs and performance-based incentives. This filing reflects significant compensation adjustments after an eight-year gap since his last equity grant.